Of
subjects with PRA >= 50% only 57% were transplanted by I year on the waitlist, as compared with 76% of those with PRA <10%. Waitlist mortality for the highly allosensitized subjects (>= PRA 50%) was 19% by 12 months. Survival at I year after transplantation was significantly lower in those with PRA >= 50% versus those with PRA <10% (73% vs 90%, respectively, p < 0.0001). Those with elevated PRA who had a negative prospective crossmatch had no difference in survival compared with those without allosensitization. There was no significant association between PRA levels and time to first rejection or development of coronary allograft vasculopathy.
CONCLUSIONS: Significant allosensitization is associated with more than a 2-fold increased risk of death within the first transplant year. Although prospective crossmatching abrogates the risk of post-transplant click here mortality, it may contribute to higher pre-transplant attrition
due to longer waitlist times. There is a critical need for strategies to minimize the impact of allosensitization and antibody-mediated rejection immediately after transplantation. J Heart Lung Transplant 2011;30:1221-7 (C) 2011 International Society for Heart and Lung Transplantation. All rights reserved.”
“BACKGROUND: Acute rejection affects more than 36% of recipients within the first year post-transplantation. The interleukin-2 (IL-2) receptor antagonist basiliximab has been ACP-196 mw associated with decreased frequency and severity of acute rejection. We investigated whether the timing of induction administration would impact the frequency and severity of acute rejection in
the first year after transplantation.
METHODS: In this study we reviewed 119 patients who underwent lung transplantation at Henry Ford Hospital from October 1994 to January 2009. Prior to January 2000 no patients received induction. From January 2000 to March 2006 the initial dose was given after implantation, and from March 2006 to 2009 basiliximab was given prior to implantation. The primary outcome was cumulative acute rejection score (CAR) in the first post-operative year comparing post- vs pre-implant induction.
RESULTS: The CAR score for pre-implant this website basiliximab was 2.5 +/- 2.3. This was significantly lower than CAR score of 4.6 +/- 3.9 in the post-implant group (p = 0.025). The no-induction group had the highest CAR score at 6.3 +/- 3.8 (p = 0.077 compared with the post group). The mean follow-up times in the post and pre group were 5.9 +/- 2.3 and 2.3 +/- 0.7 years, respectively (p < 0.001). There was no difference in freedom from bronchiolitis obliterans syndrome (BOS), survival or invasive infections between pre- and post-implant induction groups.
CONCLUSIONS: Basiliximab prior to implant is associated with a lower cumulative acute rejection score over 1 year compared with induction post-implantation. Despite a lower cumulative acute rejection score, there was no significant difference in freedom from BOS or survival.